In the general population, Syk expression in human basophils is highly variable and correlates well with the IgE-mediated responsiveness of these cells. Previous studies established that IgE-mediated stimulation results in loss of Syk expression. The current studies investigated whether stimulation through other receptors results in loss of Syk. Two classes of stimulation were examined, those that operate through the kinase Syk and those that operate through a GTP-binding protein. These studies demonstrated that aggregation of leukocyte Ig-like receptor LILRA-2 resulted in phosphorylation of Syk and c-Cbl, was inhibited by a third generation Syk inhibitor with an expected IC(50), and induced histamine release in strict proportion to release induced by anti-IgE Ab. Stimulation of LILRA-2 for 18 h resulted in modest loss of Syk that correlated with the more profound loss of Syk induced by anti-IgE Ab. Human recombinant histamine-releasing factor has also recently been shown to induce Syk phosphorylation and in the current studies has also been shown to induce loss of Syk in 18-h cultures. fMLP stimulation for 18 h was also found to induce modest loss of Syk. fMLP induced phosphorylation of c-Cbl that was sustained for at least 45 min. Phosphorylation of c-Cbl was inhibited by a Syk kinase inhibitor but with an IC(50) that was not consistent with Syk activity, suggesting another kinase was responsible for Cbl phosphorylation following fMLP. These studies demonstrate that it is possible to induce the loss of Syk expression in human basophils by a non-IgE-dependent mechanism and even by a mechanism that does directly involve Syk in the reaction complex.

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.180.6.4208DOI Listing

Publication Analysis

Top Keywords

loss syk
32
syk
16
human basophils
12
syk expression
12
basophils non-ige-dependent
8
expression human
8
current studies
8
c-cbl inhibited
8
induced anti-ige
8
modest loss
8

Similar Publications

Background: Chemotherapy-induced mucositis (CIM) significantly impacts quality of life and reduces survival in patients treated with specific chemotherapeutic agents. However, effective clinical treatments for CIM remain limited. Intravenous immunoglobulin (IVIg), a therapeutic derived from pooled human plasma, is widely used to treat inflammatory diseases.

View Article and Find Full Text PDF

CD22 blockade exacerbates neuroinflammation in Neuromyelitis optica spectrum disorder.

J Neuroinflammation

November 2024

Department of Neurology, Tangdu Hospital, Air Force Medical University, Xi'an, Shaanxi, 710038, China.

Background: Neuromyelitis optica spectrum disorder (NMOSD) is an autoantibody-triggered central nervous system (CNS) demyelinating disease that primarily affects the spinal cord, optic nerves and brainstem. Among the first responders to CNS injury, microglia are prominent players that drive NMOSD lesion formation. However, the key molecular switches controlling the detrimental activity of microglia in NMOSD are poorly understood.

View Article and Find Full Text PDF

Unlabelled: Neutrophils communicate with one another and amplify their destructive power through swarming, a collective process that synchronizes the activities of multiple neutrophils against one target. The sequence of activities contributing to swarming against clusters of fungi has been recently uncovered. However, the molecular signals controlling the neutrophils' activities during the swarming process are just emerging.

View Article and Find Full Text PDF

Pulmonary arterial hypertension (PAH) is a severe disease caused by progressive distal pulmonary artery obstruction. One cause of PAH are loss-of-function mutations in the potassium channel subfamily K member 3 (KCNK3). KCNK3 encodes a two-pore domain potassium channel, which is crucial for pulmonary circulation homeostasis.

View Article and Find Full Text PDF

Neutrophil-specific Shp1 loss results in lethal pulmonary hemorrhage in mouse models of acute lung injury.

J Clin Invest

October 2024

Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of Medicine.

Article Synopsis
  • ARDS is a severe condition that leads to high rates of illness and death, with neutrophils playing a key role in its development.
  • Research shows that removing the Shp1 protein from neutrophils in mice leads to extreme inflammation and dangerous lung bleeding, suggesting that Shp1 helps regulate neutrophil activity.
  • The use of a Shp1 activator (SC43) may help control excessive neutrophil responses, presenting a potential treatment strategy for ARDS by reducing inflammation and associated lung damage.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!